BACKGROUND: The optimal lifestyle intervention that reverses diabetes risk factors is not known. OBJECTIVE: We examined the effect of a low-glycemic index (GI) diet and exercise intervention on glucose metabolism and insulin secretion in obese, prediabetic individuals. DESIGN:Twenty-two participants [mean ± SEM age: 66 ± 1 y; body mass index (in kg/m(2)): 34.4 ± 0.8] underwent a 12-wk exercise-training intervention (1 h/d for 5 d/wk at ≈ 85% of maximum heart rate) while randomly assigned to receive either a low-GI diet (LoGIX; 40 ± 0.3 units) or a high-GI diet (HiGIX; 80 ± 0.6 units). Body composition (measured by using dual-energy X-ray absorptiometry and computed tomography), insulin sensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glucose), and oral glucose-induced insulin and incretin hormone secretion were examined. RESULTS: Both groups lost equal amounts of body weight (-8.8 ± 0.9%) and adiposity and showed similar improvements in peripheral tissue (+76.2 ± 14.9%) and hepatic insulin sensitivity (+27.1 ± 7.1%) (all P < 0.05). However, oral glucose-induced insulin secretion was reduced only in the LoGIX group (6.59 ± 0.86 nmol in the prestudy compared with 4.70 ± 0.67 nmol in the poststudy, P < 0.05), which was a change related to the suppressed postprandial response of glucose-dependent insulinotropic polypeptide. When corrected for changes in β cell glucose exposure, changes in insulin secretion were attenuated in the LoGIX group but became significantly elevated in the HiGIX group. CONCLUSIONS: Although lifestyle-induced weight loss improves insulin resistance in prediabetic individuals, postprandial hyperinsulinemia is reduced only when a low-GI diet is consumed. In contrast, a high-GI diet impairs pancreatic β cell and intestinal K cell function despite significant weight loss. These findings highlight the important role of the gut in mediating the effects of a low-GI diet on type 2 diabetes risk reduction.
RCT Entities:
BACKGROUND: The optimal lifestyle intervention that reverses diabetes risk factors is not known. OBJECTIVE: We examined the effect of a low-glycemic index (GI) diet and exercise intervention on glucose metabolism and insulin secretion in obese, prediabetic individuals. DESIGN: Twenty-two participants [mean ± SEM age: 66 ± 1 y; body mass index (in kg/m(2)): 34.4 ± 0.8] underwent a 12-wk exercise-training intervention (1 h/d for 5 d/wk at ≈ 85% of maximum heart rate) while randomly assigned to receive either a low-GI diet (LoGIX; 40 ± 0.3 units) or a high-GI diet (HiGIX; 80 ± 0.6 units). Body composition (measured by using dual-energy X-ray absorptiometry and computed tomography), insulin sensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glucose), and oral glucose-induced insulin and incretin hormone secretion were examined. RESULTS: Both groups lost equal amounts of body weight (-8.8 ± 0.9%) and adiposity and showed similar improvements in peripheral tissue (+76.2 ± 14.9%) and hepatic insulin sensitivity (+27.1 ± 7.1%) (all P < 0.05). However, oral glucose-induced insulin secretion was reduced only in the LoGIX group (6.59 ± 0.86 nmol in the prestudy compared with 4.70 ± 0.67 nmol in the poststudy, P < 0.05), which was a change related to the suppressed postprandial response of glucose-dependent insulinotropic polypeptide. When corrected for changes in β cell glucose exposure, changes in insulin secretion were attenuated in the LoGIX group but became significantly elevated in the HiGIX group. CONCLUSIONS: Although lifestyle-induced weight loss improves insulin resistance in prediabetic individuals, postprandial hyperinsulinemia is reduced only when a low-GI diet is consumed. In contrast, a high-GI diet impairs pancreatic β cell and intestinal K cell function despite significant weight loss. These findings highlight the important role of the gut in mediating the effects of a low-GI diet on type 2 diabetes risk reduction.
Authors: Kristina M Utzschneider; Darcy B Carr; Suzanne M Barsness; Steven E Kahn; Robert S Schwartz Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Thomas P J Solomon; Jacob M Haus; Karen R Kelly; Michael Rocco; Sangeeta R Kashyap; John P Kirwan Journal: Diabetes Care Date: 2010-03-03 Impact factor: 19.112
Authors: Barbara A Gower; Laura Lee Goree; Paula C Chandler-Laney; Amy C Ellis; Krista Casazza; Wesley M Granger Journal: Metabolism Date: 2011-09-23 Impact factor: 8.694
Authors: Karen R Kelly; Sankar D Navaneethan; Thomas P J Solomon; Jacob M Haus; Marc Cook; Hope Barkoukis; John P Kirwan Journal: Med Sci Sports Exerc Date: 2014 Impact factor: 5.411
Authors: Ciarán E Fealy; Stephan Nieuwoudt; Julie A Foucher; Amanda R Scelsi; Steven K Malin; Mangesh Pagadala; Lauren A Cruz; Miranda Li; Michael Rocco; Bartolome Burguera; John P Kirwan Journal: Exp Physiol Date: 2018-07 Impact factor: 2.969
Authors: John P Kirwan; Steven K Malin; Amanda R Scelsi; Emily L Kullman; Sankar D Navaneethan; Mangesh R Pagadala; Jacob M Haus; Julianne Filion; Jean-Philippe Godin; Sunil Kochhar; Alastair B Ross Journal: J Nutr Date: 2016-10-19 Impact factor: 4.798
Authors: Steven K Malin; Nicole Niemi; Thomas P J Solomon; Jacob M Haus; Karen R Kelly; Julianne Filion; Michael Rocco; Sangeeta R Kashyap; Hope Barkoukis; John P Kirwan Journal: Ann Nutr Metab Date: 2012 Impact factor: 3.374
Authors: Steven K Malin; Stephen Finnegan; Ciaran E Fealy; Julianne Filion; Michael B Rocco; John P Kirwan Journal: Metab Syndr Relat Disord Date: 2013-11-27 Impact factor: 1.894
Authors: Steven K Malin; Thomas P J Solomon; Alecia Blaszczak; Stephen Finnegan; Julianne Filion; John P Kirwan Journal: Am J Physiol Endocrinol Metab Date: 2013-09-17 Impact factor: 4.310